Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
carboplatin + epirubicin + fluorouracil
- Development stage
- Unknown
- Lead developer
- Johnson Matthey
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
This is a combination chemotherapy regimen consisting of three cytotoxic agents: carboplatin, epirubicin, and fluorouracil (5-fluorouracil). Carboplatin is a platinum-based compound that induces DNA crosslinking and apoptosis. Epirubicin is an anthracycline antibiotic that intercalates into DNA, inhibiting topoisomerase II and generating free radicals leading to cell death. Fluorouracil is an antimetabolite that inhibits thymidylate synthase, disrupting DNA synthesis. The ECarboF regimen has been studied primarily in metastatic hormone-refractory prostate cancer as well as advanced or metastatic breast cancer. It aims to provide effective tumor control with a toxicity profile considered manageable compared to regimens containing cisplatin[1][2][3][4][5].
- Other names
- epirubicin carboplatin and 5-fluorouracilECarboF regimen
02
Targets
TOP2A (DNA topoisomerase II)DNATS (Thymidylate synthase)
Beyond the preview
Go deeper on carboplatin + epirubicin + fluorouracil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on carboplatin + epirubicin + fluorouracil.